217 related articles for article (PubMed ID: 18070884)
1. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.
Tartari CJ; Gunby RH; Coluccia AM; Sottocornola R; Cimbro B; Scapozza L; Donella-Deana A; Pinna LA; Gambacorti-Passerini C
J Biol Chem; 2008 Feb; 283(7):3743-50. PubMed ID: 18070884
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
3. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
Bischof D; Pulford K; Mason DY; Morris SW
Mol Cell Biol; 1997 Apr; 17(4):2312-25. PubMed ID: 9121481
[TBL] [Abstract][Full Text] [Related]
4. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
Cussac D; Greenland C; Roche S; Bai RY; Duyster J; Morris SW; Delsol G; Allouche M; Payrastre B
Blood; 2004 Feb; 103(4):1464-71. PubMed ID: 14563642
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
Ouyang T; Bai RY; Bassermann F; von Klitzing C; Klumpen S; Miething C; Morris SW; Peschel C; Duyster J
J Biol Chem; 2003 Aug; 278(32):30028-36. PubMed ID: 12748172
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Hegazy SA; Wang P; Anand M; Ingham RJ; Gelebart P; Lai R
J Biol Chem; 2010 Jun; 285(26):19813-20. PubMed ID: 20424160
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
[TBL] [Abstract][Full Text] [Related]
9. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
Bai RY; Dieter P; Peschel C; Morris SW; Duyster J
Mol Cell Biol; 1998 Dec; 18(12):6951-61. PubMed ID: 9819383
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2.
Koshiba S; Li H; Motoda Y; Tomizawa T; Kasai T; Tochio N; Yabuki T; Harada T; Watanabe S; Tanaka A; Shirouzu M; Kigawa T; Yamamoto T; Yokoyama S
J Struct Funct Genomics; 2010 Jun; 11(2):125-41. PubMed ID: 20454865
[TBL] [Abstract][Full Text] [Related]
11. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
Ma Z; Cools J; Marynen P; Cui X; Siebert R; Gesk S; Schlegelberger B; Peeters B; De Wolf-Peeters C; Wlodarska I; Morris SW
Blood; 2000 Mar; 95(6):2144-9. PubMed ID: 10706887
[TBL] [Abstract][Full Text] [Related]
12. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
[TBL] [Abstract][Full Text] [Related]
13. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
[TBL] [Abstract][Full Text] [Related]
14. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
Wu F; Wang P; Zhang J; Young LC; Lai R; Li L
Mol Cell Proteomics; 2010 Jul; 9(7):1616-32. PubMed ID: 20393185
[TBL] [Abstract][Full Text] [Related]
15. NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis.
McDonnell SR; Hwang SR; Basrur V; Conlon KP; Fermin D; Wey E; Murga-Zamalloa C; Zeng Z; Zu Y; Elenitoba-Johnson KS; Lim MS
Oncogene; 2012 Aug; 31(32):3733-40. PubMed ID: 22179823
[TBL] [Abstract][Full Text] [Related]
16. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.
Donella-Deana A; Marin O; Cesaro L; Gunby RH; Ferrarese A; Coluccia AM; Tartari CJ; Mologni L; Scapozza L; Gambacorti-Passerini C; Pinna LA
Biochemistry; 2005 Jun; 44(23):8533-42. PubMed ID: 15938644
[TBL] [Abstract][Full Text] [Related]
17. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
18. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
19. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
20. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
